BioCentury | Apr 6, 2019

Big caps under pressure

...Mid-2019 Epizyme Inc. (NASDAQ:EPZM) Tazemetostat Treat epithelioid sarcoma Submit NDA 2Q19 Evofem Biosciences Inc. (NASDAQ:EVFM) Amphora...
BioCentury | Jan 11, 2019
Clinical News

Evofem to resubmit NDA for hormone-free contraceptive

...on Dec. 17 that it plans to resubmit an NDA to FDA next quarter for Amphora...
...after the product met the primary endpoint in the single-arm, confirmatory Phase III AMPOWER trial. Amphora... 21-35 day cycles of Amphora use. Evofem Biosciences Inc. (NASDAQ:EVFM), San Diego, Calif. Product: Amphora...
BioCentury | Aug 22, 2016
Clinical News

Amphora: Phase I started

...Evofem began a double-blind, U.S. Phase I trial to compare 3, 4, and 5 g Amphora... treatment in about 100 healthy female volunteers. Evofem Inc. , San Diego, Calif. Product: Amphora...
BioCentury | Jan 15, 2007
Company News

Amphora management update

Amphora Discovery Corp. , Research Triangle Park, N.C. Business: Chemistry, Genomics, Supply/Service Promoted: William Janzen to president and COO from VP of operations and CTO WIR Staff...
BioCentury | Jan 15, 2007
Company News

Amphora, Genentech deal

...from Amphora, including preclinical drug candidates for an undisclosed target. Financial terms were not disclosed. Amphora...
BioCentury | Feb 27, 2006
Company News

Amphora, Nanosyn Inc. deal

...provide chemistry services to Amphora to assist in the design and synthesis of small molecules. Amphora...
...will receive an upfront fee and research funding and is eligible for milestones and royalties. Amphora...
BioCentury | May 2, 2005

MPM's portfolio

...ND 5/9/03 $55.3 Michael Steinmetz Affymax Cancer; Hematology U.S. Series C 6/23/03 $40.0 Nicholas Galakatos Amphora...
BioCentury | Apr 11, 2005
Company News

Xenome board of directors update

...sciences at Structural GenomiX Inc.; and Jeff Riley, VP of finance and corporate development at Amphora...
BioCentury | Jan 17, 2005
Company News

Amphora Discovery Inc., J&J deal

...collaboration. Amphora will receive an upfront fee and research funding, plus potential milestones and royalties. Amphora...
BioCentury | Jan 10, 2005
Company News

Amphora, JNJ inflammation deal Amphora's compounds against an undisclosed inflammation target and to compounds discovered during the collaboration. Amphora...
Items per page:
1 - 10 of 34